Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator (SARM), for Acute Hip Fracture SAN DIEGO, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or...

Viking Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update Phase 2 Clinical Studies to Begin in Acute Hip Fracture and Hypercholesterolemia/Fatty Liver Disease Completes $22.3 Million IPO SAN DIEGO, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Viking...

Viking Therapeutics to Conduct Phase 2 Trial of VK2809 in Patients With Cholesterolemia and Fatty Liver Disease SAN DIEGO, July 29, 2015 (GLOBE NEWSWIRE) -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or...